Stocks · News reference

B. Riley Securities Maintains Buy on Anika Therapeutics, Raises Price Target to $21

Jul 30, 2026, 4:30 PMBenzinga Newsdesk

Read original source More stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Jul 30, 2026, 4:30 PM
Checked: Jul 30, 2026, 4:29 PM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaJul 29, 2026, 1:14 PMBenzinga Newsdesk
Anika Therapeutics shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY26 sales guidance with its midpoint above estimates.
Read original at benzinga
ANIK
SEC EDGARJul 29, 2026, 11:20 AMSEC EDGAR
8-K filing — Anika Therapeutics, Inc. (ANIK)
Filed: 2026-07-29 AccNo: 0001171843-26-004977 Size: 408 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgar
ANIK
BenzingaJul 29, 2026, 11:10 AMBenzinga Newsdesk
Anika Therapeutics Raises FY2026 Sales Guidance from $114.000M-$122.500M to $118.460M-$124.101M vs $118.612M Est
Read original at benzinga
ANIK